Can-Fite Advances Therapeutic Pipeline Amidst Market Opportunities
Company Announcements

Can-Fite Advances Therapeutic Pipeline Amidst Market Opportunities

Can-Fite BioPharma (CANF) has released an update.

Can-Fite BioPharma Ltd, a clinical-stage biopharmaceutical company, is advancing its pipeline of small molecule therapeutic products targeting cancer, liver and inflammatory diseases, and erectile dysfunction. With a focus on the A3 adenosine receptor as a therapeutic target, the company is developing drugs for significant market opportunities, including a forecasted $11.3 billion psoriasis drug market by 2025. Despite promising prospects, the company cautions about forward-looking statements due to various risks, including financial uncertainties and the competitive nature of the biopharmaceutical industry.

For further insights into CANF stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCan-Fite BioPharma Secures Australian Patent for Obesity Drug
TheFlyCan-Fite BioPharma announces an update related to IP status of Namodenoson
TipRanks Auto-Generated NewsdeskCan-Fite BioPharma Secures Lucrative Deal with Vetbiolix
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App